BCKDK and breast cancer: To evaluate synergy between these inhibitors and paclitaxel, we used OVCAR-4, COV-362, COV-318 and FUOV-1 ovarian cancer cells which showed a range of expression levels of BCKDK and BCKDH as well as the three breast cancer cell lines.